Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A
William Lostal(Inserm), Isabelle Richard(Inserm), Henk Granzier(University of Arizona), Jochen Gohlke(University of Arizona), Laurence Suel(Inserm), Zaher Elbeck(Uppsala University), Xidan Li(Integrated Cardio Metabolic Centre), John E. Smith(University of Arizona), Guillaume Corre(Inserm), Jack‐Yves Deschamps(Oniris), Ralph Knöll(Integrated Cardio Metabolic Centre), Heather Best(The University of Sydney), Karine Charton(Inserm), Nathalie Bourg(Inserm), Carinne Roudaut(Inserm), Marine Faivre(Inserm)
Cited by 26
Related Papers
Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A
|Cell|1995|998
Recessive truncating titin gene, <i>TTN</i> , mutations presenting as centronuclear myopathy
|Neurology|2013|217
Congenital Titinopathy: Comprehensive characterization and pathogenic insights
|Annals of Neurology|2018|166
The Sarcomeric Z‐Disc and Z‐Discopathies
|BioMed Research International|2011|125
Liver macrophages regulate systemic metabolism through non-inflammatory factors
|Nature Metabolism|2019|111